GLP-1 receptor agonists also reduce the three components of MACE, including CV mortality (reduced by 13%), nonfatal stroke (reduced by 16%) and nonfatal myocardial infarction (reduced by 9%, although the level of significance was not reached)
Insurance coverage of GLP-1 medications for obesity has invariably been relatively poor across all markets, including commercial and Medicaid
Weight Loss but Mixed Results With Victoza and Ozempic Victoza helped me lose a bunch of weight with no side effects
Trial data showed that Saxenda , in combination with a reduced-calorie diet and increased physical activity, resulted in significantly greater weight loss in some patients than reduced-calorie diet and physical activity alone
Common adverse reactions included nausea, diarrhea, and vomiting.172 GSBR-1290 GSBR-1290 is an oral small molecule GLP-1RA developed by Structure Therapeutics, aimed at treating T2DM and obesity